Transverse myelitis interventions
Jump to navigation
Jump to search
|
Transverse myelitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Transverse myelitis interventions On the Web |
|
American Roentgen Ray Society Images of Transverse myelitis interventions |
|
Risk calculators and risk factors for Transverse myelitis interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- There is no single procedural intervention required for every patient with transverse myelitis. Intervention selection depends on attack severity, response to medical therapy, neurological deficits, complications, functional goals, and the identified cause.
- Therapeutic plasma exchange (TPE) is the principal disease-directed procedure for a severe presumed immune-mediated myelitis attack or an attack with insufficient early improvement after high-dose intravenous (IV) corticosteroid therapy.[1][2]
- Other interventions do not directly suppress spinal cord inflammation. They address mobility and independence, spasticity, neurogenic bladder or bowel dysfunction, and complications of immobility.
- Drug regimens are addressed in Transverse myelitis medical therapy, and operative procedures are addressed in Transverse myelitis surgery.
Interventions
Acute disease-directed procedures
| Intervention | When to consider | Clinical guidance |
|---|---|---|
| Therapeutic plasma exchange (TPE) | Severe myelitis at presentation; rapid neurological progression; major motor, sensory, respiratory, or autonomic impairment; or insufficient recovery within the first days of high-dose corticosteroid treatment. | TPE should be considered promptly rather than after a prolonged period of ineffective treatment. In severe neuromyelitis optica spectrum disorder (NMOSD)-associated myelitis, it may be started concurrently with corticosteroids or used as first-line apheresis in selected patients. Current European consensus commonly uses approximately 5 procedures, performed daily or every other day; additional procedures may be considered according to response and specialist assessment. Treatment volume, replacement fluid, vascular access, and the total number of procedures must be individualized.[1][2] |
| Immunoadsorption | Alternative apheresis procedure for severe NMOSD-associated myelitis when the technique and appropriate expertise are available. | European consensus accepts immunoadsorption as an alternative to TPE. Experience and supporting evidence are greater for TPE, and immunoadsorption availability varies substantially between centers.[1] |
Safety during apheresis
- TPE or immunoadsorption should be performed by an experienced apheresis team with neurological reassessment during the treatment course.
- Monitor vascular access, hemodynamic status, blood count, electrolytes, coagulation parameters, fibrinogen, bleeding, infection, allergic reactions, and procedure-related complications.[2]
- Coordinate the timing of TPE with other infused therapies because plasma exchange can remove circulating therapeutic antibodies and other plasma-bound treatments.[2]
Multidisciplinary neurorehabilitation
- Begin coordinated rehabilitation when the patient is medically and neurologically stable enough to participate. The plan should be individualized, goal-directed, reviewed as recovery evolves, and coordinated across acute, inpatient, outpatient, and community settings.[3]
| Intervention | Individualized goals |
|---|---|
| Physical therapy | Positioning; active or assisted range-of-motion work; progressive strengthening; prevention of contracture and deconditioning; sitting and standing tolerance; balance; transfers; wheelchair skills; and task-specific gait training when appropriate. For ambulatory patients with chronic incomplete spinal-cord dysfunction, task-specific walking practice may improve walking speed and endurance; the intensity and assistance required must be individualized.[3][4] |
| Occupational therapy | Retraining and adaptation for activities of daily living, upper-limb function, self-care, transfers, energy conservation, return to education or work, caregiver training, and selection of appropriate equipment or environmental modifications.[3] |
| Mobility, seating, and orthotic interventions | Select and reassess walking aids, braces, wheelchairs, seating systems, and pressure-relieving equipment according to strength, sensation, balance, endurance, body dimensions, skin risk, home environment, and the patient's participation goals.[3] |
Spasticity procedures
- Treat aggravating factors and establish specific functional goals before performing an invasive spasticity intervention. Rehabilitation therapy remains the foundation of management, and reducing tone excessively may worsen standing, transfers, or walking.[5]
| Procedure | Appropriate use and precautions |
|---|---|
| Targeted botulinum toxin type A injection | Consider for focal or segmental disabling spasticity when defined goals include improved positioning, hygiene, comfort, passive range of motion, brace tolerance, gait, or task performance. Injection should be integrated with stretching, splinting, and functional therapy, followed by outcome reassessment.[5][6] |
| Specialist intrathecal baclofen assessment and screening trial | Consider for severe multisegmental or generalized disabling spasticity that remains inadequately controlled or is not tolerated with less-invasive management. Establish measurable goals before a screening trial. Permanent therapy requires an implanted pump, reliable follow-up, refill access, and education about potentially life-threatening overdose or abrupt-withdrawal syndromes; it is not a routine first-line intervention.[5][6] |
Neuro-urological interventions
- Bladder intervention should be individualized according to emptying ability, post-void residual urine, bladder pressure, hand function, cognition, mobility, infection history, upper-urinary-tract risk, caregiver support, and patient preference.[7][8]
| Intervention | Appropriate use and precautions |
|---|---|
| Intermittent catheterization | Preferred bladder-emptying intervention when urinary retention or ineffective emptying is clinically important and spontaneous voiding is unsafe or inadequate. Use shared decision-making and provide practical training in technique, frequency, catheter care, and recognition of complications. The schedule should be individualized to bladder volumes, fluid intake, urodynamic risk, and daily circumstances.[7][8] |
| Temporary indwelling urinary catheter | May be necessary during acute severe retention when intermittent catheterization is temporarily infeasible. Reassess the indication frequently and remove it as soon as a safer sustainable emptying plan is established. Chronic urethral or suprapubic catheterization should not be chosen solely because transverse myelitis is present and should be avoided when a suitable lower-risk alternative is feasible.[7][8] |
| Detrusor botulinum toxin type A injection | Consider through neuro-urology for neurogenic detrusor overactivity that remains inadequately controlled with conservative and pharmacological management. Before treatment, discuss urinary retention, urinary tract infection, hematuria, the possible need for intermittent catheterization, and the requirement for follow-up.[7][8] |
Neurogenic bowel interventions
- Establish an individualized bowel program according to stool consistency, continence, mobility, hand function, caregiver availability, anorectal findings, and the neurological pattern of bowel dysfunction.
- Scheduled toileting, appropriate positioning, digital rectal stimulation, or manual evacuation may be incorporated when clinically indicated and taught by trained professionals.
- Transanal irrigation may be considered when a structured conservative bowel program is insufficient and before operative options are pursued. Training, contraindication assessment, and monitoring for pain, bleeding, autonomic symptoms, or other complications are required.[9]
Pressure-injury prevention
- Patients with weakness, sensory loss, impaired mobility, or incontinence require an individualized pressure-injury prevention plan.
- Interventions may include regular skin inspection, repositioning and pressure off-loading, an appropriate mattress or support surface, wheelchair seating assessment, moisture and continence management, and education of the patient and caregivers. Frequency and equipment should be individualized rather than prescribed as a single schedule for every patient.[10]
Clinical sequencing
- In a severe presumed immune-mediated attack, assess early for TPE while acute medical treatment is being administered.
- Once medically stable, perform a multidisciplinary functional assessment and begin a personalized rehabilitation plan.
- Identify specific complications requiring procedural management, particularly bladder-emptying failure, bowel dysfunction, disabling spasticity, and pressure-injury risk.
- Reassess interventions as neurological recovery, functional goals, caregiver resources, and the underlying diagnosis evolve.
References
- ↑ 1.0 1.1 1.2 Kümpfel T, Giglhuber K, Aktas O, et al.; Neuromyelitis Optica Study Group. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders—revised recommendations of the Neuromyelitis Optica Study Group. Part II: Attack therapy and long-term management. Journal of Neurology. 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z. PMID: 37676297. Correction: Journal of Neurology. 2024;271(6):3702-3707. doi:10.1007/s00415-024-12288-2.
- ↑ 2.0 2.1 2.2 2.3 Zantek ND, Alquist CR, Hofmann JC, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the tenth special issue. Journal of Clinical Apheresis. 2026;41(Suppl 2):e70141. doi:10.1002/jca.70141. PMID: 42747330.
- ↑ 3.0 3.1 3.2 3.3 National Institute for Health and Care Excellence. Rehabilitation for chronic neurological disorders including acquired brain injury. NICE guideline NG252. Published October 15, 2025. Accessed October 2, 2026.
- ↑ Hornby TG, Reisman DS, Ward IG, et al.; Locomotor Clinical Practice Guideline Appraisal Team. Clinical practice guideline to improve locomotor function following chronic stroke, incomplete spinal cord injury, and brain injury. Journal of Neurologic Physical Therapy. 2020;44(1):49-100. doi:10.1097/NPT.0000000000000303. PMID: 31834165.
- ↑ 5.0 5.1 5.2 Verduzco-Gutierrez M, Raghavan P, Pruente J, et al. American Academy of Physical Medicine and Rehabilitation consensus guidance on spasticity assessment and management. PM&R. 2024;16(8):864-887. doi:10.1002/pmrj.13211. PMID: 38770827.
- ↑ 6.0 6.1 Biering-Sørensen B, Stevenson V, Bensmail D, et al. European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A. Journal of Rehabilitation Medicine. 2022;54:jrm00241. doi:10.2340/16501977-2877.
- ↑ 7.0 7.1 7.2 7.3 Ginsberg DA, Boone TB, Cameron AP, et al. The American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. The Journal of Urology. 2021;206(5):1106-1113. doi:10.1097/JU.0000000000002239. PMID: 34495688.
- ↑ 8.0 8.1 8.2 8.3 Sartori AM, Kessler TM, Ecclestone H, et al. European Association of Urology Guidelines on Neuro-urology: summary of the 2026 update. European Urology. 2026;90(3):241-253. doi:10.1016/j.eururo.2026.04.012. PMID: 42457452.
- ↑ Johns J, Krogh K, Rodriguez GM, et al. Management of neurogenic bowel dysfunction in adults after spinal cord injury: clinical practice guideline for health care providers. Topics in Spinal Cord Injury Rehabilitation. 2021;27(2):75-151. doi:10.46292/sci2702-75. PMID: 34108835.
- ↑ National Pressure Injury Advisory Panel, European Pressure Ulcer Advisory Panel, and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. 4th ed. Haesler E, ed. 2026. Accessed October 2, 2026.